Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

New Cancer Markers

New Cancer Markers Physicians treating patients with head and neck cancer may have new clinical options for predicting recurrences and staging treatment. Researchers at the University of Pittsburgh School of Medicine report that levels of epidermal growth factor receptor (EGFR) and its ligand, transforming growth factor α (TGF-α), can predict clinical outcomes as accurately as the traditional method of cervical lymph node dissection. Their finding is based on examinations of tumor tissue taken from 91 patients with head and neck cancer, which they compared with previous studies of patients without the disease. The research team used monoclonal antibodies and computerized image analysis to measure levels of EGFR and TGF-α. In their report, published June 3 in the Journal of the National Cancer Institute, the researchers said patients with head and neck cancer had elevated levels of the proteins in the tumor tissue, while patients without the disease had low levels. "We could use this information to identify patients at risk for recurrent disease and develop a targeted therapy based on the biology of these markers," said Jennifer Rubin Grandis, MD, lead author of the study. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png JAMA American Medical Association

New Cancer Markers

JAMA , Volume 280 (4) – Jul 22, 1998

New Cancer Markers

Abstract

Physicians treating patients with head and neck cancer may have new clinical options for predicting recurrences and staging treatment. Researchers at the University of Pittsburgh School of Medicine report that levels of epidermal growth factor receptor (EGFR) and its ligand, transforming growth factor α (TGF-α), can predict clinical outcomes as accurately as the traditional method of cervical lymph node dissection. Their finding is based on examinations of tumor tissue taken from...
Loading next page...
 
/lp/american-medical-association/new-cancer-markers-3gbw4BmyW0
Publisher
American Medical Association
Copyright
Copyright © 1998 American Medical Association. All Rights Reserved.
ISSN
0098-7484
eISSN
1538-3598
DOI
10.1001/jama.280.4.315
Publisher site
See Article on Publisher Site

Abstract

Physicians treating patients with head and neck cancer may have new clinical options for predicting recurrences and staging treatment. Researchers at the University of Pittsburgh School of Medicine report that levels of epidermal growth factor receptor (EGFR) and its ligand, transforming growth factor α (TGF-α), can predict clinical outcomes as accurately as the traditional method of cervical lymph node dissection. Their finding is based on examinations of tumor tissue taken from 91 patients with head and neck cancer, which they compared with previous studies of patients without the disease. The research team used monoclonal antibodies and computerized image analysis to measure levels of EGFR and TGF-α. In their report, published June 3 in the Journal of the National Cancer Institute, the researchers said patients with head and neck cancer had elevated levels of the proteins in the tumor tissue, while patients without the disease had low levels. "We could use this information to identify patients at risk for recurrent disease and develop a targeted therapy based on the biology of these markers," said Jennifer Rubin Grandis, MD, lead author of the study.

Journal

JAMAAmerican Medical Association

Published: Jul 22, 1998

Keywords: cancer

There are no references for this article.